UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

2023 GEIS Guidelines for gastrointestinal stromal tumors

Therapeutic Advances in Medical Oncology, 2023-01, Vol.15, p.17588359231192388

2023

Volltextzugriff (PDF)

Abiraterone after docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients (p) in an off-protocol routine clinical setting

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e16087-e16087

2014

Volltextzugriff (PDF)

Abstract 3405: Caveolin-1 modulates the metastatic ability of Ewing's sarcoma

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.3405-3405

2010

Volltextzugriff (PDF)

Abstract 3827: Caveolin-1 acts as a tumor suppressor promoting muscular differentiation in alveolar rhabdomyosarcomas

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3827-3827

2013

Volltextzugriff (PDF)

Abstract 432: Loss of MGMT promoter methylation and resistance to cisplatin in non-seminomatous germ cell tumors

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.432-432

2016

Volltextzugriff (PDF)

Abstract A18: Epigenetic profiling uncovers the suppressive role of caveolae in Ewing sarcoma

Cancer research (Chicago, Ill.), 2016-03, Vol.76 (5_Supplement), p.A18-A18

2016

Volltextzugriff (PDF)

Abstract CT040: Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT040-CT040

2021

Volltextzugriff (PDF)

Abstract CT042: Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT042-CT042

2021

Volltextzugriff (PDF)

Abstract CT187: Overall survival (OS) by response during “induction” from the global, randomized Phase III IMvigor130 study of atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated metastatic urothelial carcinoma (mUC)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT187-CT187

2021

Volltextzugriff (PDF)

ac conductance in granular insulating Co-ZrO 2 thin films: A universal response

Physical review. B, Condensed matter and materials physics, 2009-03, Vol.79 (9), Article 094201

2009

Volltextzugriff (PDF)

ac conductance in granular insulating Co-ZrO{sub 2} thin films: A universal response

Physical review. B, Condensed matter and materials physics, 2009-03, Vol.79 (9)

2009

Volltextzugriff (PDF)

Active surveillance before sequential targeted therapy in patients with metastatic renal cell carcinoma

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15582-e15582

2015

Volltextzugriff (PDF)

Active surveillance in asymptomatic or minimally symptomatic renal cell carcinoma: Retrospective analyses of a cohort of three oncological centers from Spain

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.441-441

2015

Volltextzugriff (PDF)

Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.550-550

2019

Volltextzugriff (PDF)

Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.522-522

2017

Volltextzugriff (PDF)

Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.434-434

2021

Volltextzugriff (PDF)

Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.LBA440-LBA440

2023

Volltextzugriff (PDF)

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

The Lancet (British edition), 2020-05, Vol.395 (10236), p.1547-1557

2020

Volltextzugriff (PDF)

AUREA study: Atezolizumab (Atezo) combined with split-dose gemcitabine plus cisplatin (s-GC) in locally advanced or metastatic urothelial cancer (LA/mUC): A SOGUG study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS4589-TPS4589

2021

Volltextzugriff (PDF)

Bcl-x L inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas

Scientific reports, 2019-12, Vol.9 (1), p.3816

2019

Volltextzugriff (PDF)

Bcl-xL inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas

Scientific reports, 2019-03, Vol.9 (1), p.3816-3816, Article 3816

2019

Volltextzugriff (PDF)

Benefit of prophylactic anticoagulation before and during first-line chemotherapy on patients with metastatic germ cell tumors

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.402-402

2020

Volltextzugriff (PDF)

Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2012-10, Vol.23 Suppl 7, p.vii100-vii109

ESMO / European Sarcoma Network Working Group

2012

Volltextzugriff (PDF)

1 – 25 von 241

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(224)
Mit Volltextzugriff
(228)

Publikationsform

Sprache

Englisch
(235)
Japanisch
(24)
Spanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(128)
Life Sciences & Biomedicine
(114)
Humans
(93)
Oncology
(91)
Male
(56)
Tumors
(50)
Adult
(39)
Female
(39)
Middle Aged
(36)
Aged
(31)
Prognosis
(27)
Antineoplastic Agents - Therapeutic Use
(26)
Biological And Medical Sciences
(23)
Chemotherapy
(23)
Medical Sciences
(23)
Neoplasm Staging
(20)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(18)
Medicine
(17)
Metastasis
(17)
Cancer
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

2023 GEIS Guidelines for gastrointestinal stromal tumors

Abiraterone after docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients (p) in an off-protocol routine clinical setting

Abstract 3405: Caveolin-1 modulates the metastatic ability of Ewing's sarcoma

Abstract 3827: Caveolin-1 acts as a tumor suppressor promoting muscular differentiation in alveolar rhabdomyosarcomas

Abstract 432: Loss of MGMT promoter methylation and resistance to cisplatin in non-seminomatous germ cell tumors

Abstract A18: Epigenetic profiling uncovers the suppressive role of caveolae in Ewing sarcoma

Abstract CT040: Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130

Abstract CT042: Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130

Abstract CT187: Overall survival (OS) by response during “induction” from the global, randomized Phase III IMvigor130 study of atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated metastatic urothelial carcinoma (mUC)

ac conductance in granular insulating Co-ZrO 2 thin films: A universal response

ac conductance in granular insulating Co-ZrO{sub 2} thin films: A universal response

Active surveillance before sequential targeted therapy in patients with metastatic renal cell carcinoma

Active surveillance in asymptomatic or minimally symptomatic renal cell carcinoma: Retrospective analyses of a cohort of three oncological centers from Spain

Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)

Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)

Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study

Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study

Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

AUREA study: Atezolizumab (Atezo) combined with split-dose gemcitabine plus cisplatin (s-GC) in locally advanced or metastatic urothelial cancer (LA/mUC): A SOGUG study

Bcl-x L inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas

Bcl-xL inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas

Benefit of prophylactic anticoagulation before and during first-line chemotherapy on patients with metastatic germ cell tumors

Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Suchergebnisse filtern